Colorectal Cancer Highlights from ASCO 2020 New standards of care for patients with MSI-H or MMRd metastatic colorectal cancer, and other key CRC results presented during the ASCO 2020 virtual meeting ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
FLORHAM PARK, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease ...
ASCO 2021 For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy ...
-Tumor control achieved in 76% of evaluable subjects irrespective of IL4R expression resulting in mOS, mPFS and PFS-12 of 15.0 months, 4.6 months and 33%, respectively- -In the Proposed Population ...
REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma or ...
C-144-01 Clinical Study at ASCO 2020 Virtual Scientific Program SAN CARLOS, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company ...
* POLYPHOR ANNOUNCES ACCEPTANCE OF BALIXAFORTIDE ABSTRACT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2020 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results